{
    "clinical_study": {
        "@rank": "90749", 
        "acronym": "P-EX", 
        "arm_group": [
            {
                "arm_group_label": "Nutritional supplement Pregnenolone", 
                "arm_group_type": "Experimental", 
                "description": "Orally two hours before exposure therapy."
            }, 
            {
                "arm_group_label": "Nutritional supplement Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Characterization of the influence of pregnenolone vs. placebo on subjective distress and\n      autonomic functioning during cognitive-behavioral exposure therapy in patients with\n      obsessive-compulsive disorder."
        }, 
        "brief_title": "Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder", 
        "condition": "Obsessive-compulsive Disorder (OCD)", 
        "condition_browse": {
            "mesh_term": [
                "Obsessive-Compulsive Disorder", 
                "Compulsive Personality Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -OCD according to DSM-IV criteria.\n\n        Exclusion Criteria:\n\n          -  Acute suicidality\n\n          -  psychotic disorders,\n\n          -  bipolar disorder\n\n          -  substance dependency\n\n          -  organic brain disorder\n\n          -  pregnancy\n\n          -  lactation\n\n          -  tuberculosis\n\n          -  gastric/duodenal ulcer\n\n          -  diabetes mellitus\n\n          -  acute inflammation\n\n          -  autoimmune disorders\n\n          -  arterial hypertension\n\n          -  therapy with glucocorticoids (up to 4 weeks ago)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949753", 
            "org_study_id": "PV4398"
        }, 
        "intervention": {
            "arm_group_label": "Nutritional supplement Pregnenolone", 
            "intervention_name": "Pregnenolone", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Obsessive-compulsive disorder (OCD)", 
            "Exposure therapy", 
            "Extinction learning", 
            "Pregnenolone"
        ], 
        "lastchanged_date": "September 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hamburg", 
                    "country": "Germany"
                }, 
                "name": "University Hospital Hamburg-Eppendorf"
            }, 
            "investigator": {
                "last_name": "Michael Kellner, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Influence of Pregnenolone on Distress and Autonomic Parameters During Cognitive-behavioral Exposure Therapy in Patients With Obsessive-compulsive Disorder", 
        "other_outcome": {
            "measure": "Salivary cortisol, noradrealine, pregnenolone; heart rate, blood pressure", 
            "safety_issue": "No", 
            "time_frame": "During exposure therapy"
        }, 
        "overall_contact": {
            "email": "kellner@uke.uni-hamburg.de", 
            "last_name": "Michael Kellner, MD, PhD"
        }, 
        "overall_official": {
            "affiliation": "Universit\u00e4tsklinikum Hamburg-Eppendorf", 
            "last_name": "Michael Kellner, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Subjective units of distress (SUD)", 
            "safety_issue": "No", 
            "time_frame": "During exposure therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949753"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Low/high frequency index of heart rate variability (L/HFI)", 
            "safety_issue": "No", 
            "time_frame": "During exposure therapy"
        }, 
        "source": "Universit\u00e4tsklinikum Hamburg-Eppendorf", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universit\u00e4tsklinikum Hamburg-Eppendorf", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}